Immunocore Holdings plc - ADR
NASDAQ:IMCR 9:57:53 AM EDT
| Market Cap (Intraday) | 1.53B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $31.26 |
| 50-Day MA | $35.15 |
| 200-Day MA | $51.86 |
Immunocore Holdings plc - ADR Stock, NASDAQ:IMCR
92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY
United Kingdom
Phone: +44.1235.438600
Number of Employees: 497
Description
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX � Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.